SÜTCÜOĞLU, O. Et Al. 2022. Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma. LANCET ONCOLOGY , vol.23, no.10 .

SÜTCÜOĞLU, O., ÖZET, A., YAZICI, O., & ÖZDEMİR, N., (2022). Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma. LANCET ONCOLOGY , vol.23, no.10.

SÜTCÜOĞLU, OSMAN Et Al. "Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma," LANCET ONCOLOGY , vol.23, no.10, 2022

SÜTCÜOĞLU, OSMAN Et Al. "Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma." LANCET ONCOLOGY , vol.23, no.10, 2022

SÜTCÜOĞLU, O. Et Al. (2022) . "Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma." LANCET ONCOLOGY , vol.23, no.10.

@article{article, author={OSMAN SÜTCÜOĞLU Et Al. }, title={Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma}, journal={LANCET ONCOLOGY}, year=2022}